



YUNG ZIP CHEMICAL

Stock Code : 4102



2025 Investors Conference

Oct. 16, 2025

Disclaimer

- ✦ This presentation and the forward-looking information mentioned in the simultaneously released related messages, including operational outlook, financial conditions, and business forecasts, are based on information obtained by the company from internal and external sources.
- ✦ The actual future operational results, financial conditions, and business outcomes of the company may differ from the forward-looking information due to various factors, including but not limited to market risks and market demand.
- ✦ The forward-looking statements in this presentation reflect the company's views on the future as of the current date. The company is not obligated to provide further notice or updates should there be any changes or adjustments to these views in the future.

CONTENTS

- Company Introduction
- Financial Performance Overview
- Business Development
- Research and Development Strategy

Company Introduction: Vision & Goals



Yung Zip Chemical Ind. Co., Ltd. established on June 8, 1978. As **the first executor of GMP API certification in Taiwan**, and with over 40 years of experience in the API industry, Yung Zip has successively passed international certifications such as **FDA, MHRA, PMDA, KFDA, HALAL and KOSHER.**

Yung Zip upholds the sustainable management philosophy of “**innovation, effectiveness and service**” while adhering to principles of honesty, reliability and rigorous business ethics.

Vision:

- Contributes to the elimination of human diseases**
- Providing the best pharmaceutical products**
- Improving the health of human beings**
- Maximizing shareholder value**
- Improving employee welfare**
- Fulfilling social responsibility**

Drugs registration


- TDMF : 16
- US DMF : 18
- EU CEP : 3
- JP MF : 3
- Other countries : 16

GMP approved

- TFDA : 16
- U.S. FDA : 5
- JP PMDA : 3

APIs

Speciality
Chemical



Synthesis Technique



Small-scale Test
Pilot Plant



GMP Certificate

CDMO
&
CMO

Subsidiary-
WAY CHEIN
Health Food
Production

Optoelectronics
Plastics
Semiconductor
Material


CDMO and CMO service
GMP procedure support
Customized service





Health Food Manufacture,
packaging and OEM

2018-2024 Consolidated Revenue



(In Thousands of New Taiwan Dollars)





Operational Resilience

- Deepen cultivation in APIs, continuously innovate and expand market presence.
- To ensure stability in the supply chain, production, and quality systems.
- In 2024, APIs account for **62.6% of revenue**

1

Financial Resilience

- Expand areas of collaboration to establish diversified sources of income, reduce reliance on a single stream, and strengthen cash flow management capabilities to ensure business stability in a changing environment.

2

Industry and Market Resilience

- Specialty chemicals: expand into new applications of chemical materials to mitigate risks.
- In 2024, revenue from contract manufacturing and specialty products accounted for 20.9%.

3

Diversification Strategy Resilience

- Invest in Taiwan Way Chein to build cross-industry contract manufacturing capabilities in health foods.
- Expand cooperation with partners and customers to form a broader industrial ecosystem.
- In 2024, Taiwan Way Chein revenue accounts for **16.5% of revenue**

4


Yung Zip is not merely pursuing growth curves, but has already built a diversified resilience mechanism capable of “withstanding risks and maintaining steady operations.”

CONTENTS

- Company Introduction
- Financial Performance Overview**
- Business Development
- Research and Development Strategy

Statement of Consolidated Comprehensive Income YUNG ZIP

Items (In Thousands of New Taiwan Dollars)	2024 H1 (Reviewed)	2025 H1 (Reviewed)	YoY
Operating Revenue	324,788	256,212	-21%
Operating costs	209,414	197,802	-6%
Gross Profit	115,374	58,410	-49%
Gross Margin	35%	23%	
Operating Expenses	58,559	56,736	-3%
Operating (Loss)	56,815	1,674	-97%
Operating Margin	17%	1%	
Other Rev. (Exp.)	9,147	(11,585)	-227%
Net Income	58,785	(6,470)	-111%
Net Margin After Tax	18%	-3%	
EPS	1.34	-0.19	



Consolidated Balance Sheet



Items (In Thousands of New Taiwan Dollars)	2023/6/30 (Reviewed)		2024/6/30 (Reviewed)		2025/6/30 (Reviewed)	
Cash and Cash Equivalents	156,674	15%	171,303	17%	99,786	11%
Receivables	120,299	12%	114,118	11%	79,860	8%
Inventories	153,496	15%	158,433	15%	144,992	16%
Long-term Investments	159,693	16%	155,192	15%	107,225	12%
Property, plant and equipment	392,836	38%	390,429	38%	405,087	44%
Other assets	48,345	4%	51,128	4%	80,501	9%
Total Assets	1,031,343	100%	1,040,603	100%	917,451	100%
Current Liabilities	163,803	16%	160,176	15%	165,019	18%
Non-current Liabilities	174,185	17%	131,538	13%	78,559	9%
Total Liabilities	337,988	33%	291,714	28%	243,578	27%
Total Shareholders' Equity	693,355	67%	748,889	72%	673,873	73%
Important Financial Indicator						
Average collection days	90		65		53	
Average inventory turnover days	144		143		148	
Current ratio	2.7		2.86		2.17	

Statement of Consolidated Cash Flows



(In Thousands of New Taiwan Dollars)	2023 H1 (Reviewed)	2024 H1 (Reviewed)	2025 H1 (Reviewed)
Cash and cash equivalents at beginning of period	144,179	124,111	133,526
Cash flows from operating activities	58,979	83,204	4,353
Cash flows from investment activities	(5,390)	(13,864)	(23,975)
Cash flows from financing activities	(41,094)	(22,148)	(14,118)
Cash and cash equivalents at end of period	156,674	171,303	99,786



CONTENTS

- Company Introduction
- Financial Performance Overview
- Business Development
- Research and Development Strategy

Jan.-Aug. Operating Revenue (2024 VS 2025)





Currency: one thousand NT dollars



Globe Market distribution


Period: Jan. – Aug. of 2024/2025



	JAN.–AUG. 2024	JAN.–AUG. 2025	DIFFERENCE
Taiwan	38%	41%	3%
Asia	49%	52%	3%
Africa	1%	1%	0%
America	9%	2%	-7%
Europe	3%	4%	1%

Product Category Analysis

Period: Jan. – Aug. of 2024/2025
Currency: one thousand NT dollars



Industry Overview



GLOBE

- The global Active Pharmaceutical Ingredients market is projected to reach USD 230–250 billion by 2025, with an average annual growth rate of around 6%. Driven by the rising prevalence of chronic diseases, population aging, and the demand for high value-added treatments, synthetic APIs will remain the mainstream segment, while biotechnology-based APIs are expected to expand rapidly.
- By 2026, the market is expected to surpass USD 252 billion, maintaining steady expansion.
- **The U.S. plans to impose high tariffs on imported pharmaceuticals, which may impact the global supply chain and cost structure. This move is expected to lead to higher prices for generic drugs in the U.S. and potential shortages of certain medications.**
- These regulatory changes are prompting pharmaceutical companies worldwide to readjust supply chains, strengthen manufacturing technologies, and enhance quality systems. For Taiwanese API manufacturers, this presents both challenges and opportunities. By reinforcing quality standards, upgrading technology, and diversifying export markets, Taiwan can improve its global competitiveness and capture new opportunities arising from supply chain realignments..

YUNG ZIP CHEMICAL

- In 2025, we plan to file one Drug permit license application, followed by two additional applications in 2026.
- Three new pipeline products are expected to enter the validation stage in 2026.
- We continue to actively pursue collaborations with innovative pharmaceutical companies in both API development and formulation projects. Through API research and manufacturing, and formulation promotion, we aim to strengthen our presence in local markets.. This strategic direction will open up a diversified growth pathway for us, positioning us as an ideal partner from early-stage drug development to commercial-scale productionn.

CONTENTS

- Company Introduction
- Financial Performance Overview
- Business Development
- Research and Development Strategy

Research and Development Strategy

Five Core Pillars Driving Innovation and Sustainable Growth

In response to the increasingly fierce competition and sustainability challenges in the pharmaceutical industry, we have formulated **five core R&D strategies** aimed at enhancing our **market competitiveness, industrial value, and long-term growth momentum** through **precise strategic planning and deep collaboration**.



Enhancing Process Efficiency and ESG Design

- Improve process efficiency to **significantly reduce production costs and increase capacity**
- Strengthen **technical autonomy in key intermediates** to ensure a **stable and resilient supply chain**.
- Implement **ESG principles** to develop **circular economy processes**, achieving **low-carbon production and resource efficiency**.



Deep Development of the API Market

- Focus on **high-value and orphan drug products** to **maximize production efficiency and product profitability**.
- Expand **product portfolios within the same therapeutic areas** to enhance **market penetration and diversification**.
- Anticipate **patent cliff trends** to **capture early opportunities and increase market share** in the generic drug segment.



Clinical New Drug Development and Strategic Partnerships

- Establish **strategic alliances with formulation manufacturers** to jointly develop **generic drugs with strong market potential** as patents expire.
- Provide **CDMO services** to support **new drug companies** in **clinical process development and product registration**.
- Supply **GMP-compliant clinical trial materials**, positioning the company as a **preferred partner and trusted supplier**.



Expansion of Professional Contract Manufacturing Services (CMO/CDMO)

- Actively expand **CMO/CDMO businesses** for **active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals**.
- Establish **long-term and stable strategic partnerships** with **leading global pharmaceutical companies**.
- Continuously **expand production capacity and service scope** to meet **diverse client needs**.



Innovation in Specialty Chemicals and Pharmaceutical Intermediate Markets

- Develop **new product lines of high-value-added specialty chemicals and advanced materials**, including **non-pharmaceutical and optoelectronic applications**.
- **Expand production scope** to achieve **diversified revenue growth**
- Strengthen **vertical integration of the supply chain** to secure **market supply stability and competitive advantage**.

□ Strategic Goals and Vision

- Through the integration and synergy of the five core strategies, we will establish a **comprehensive high-value chain** spanning from **upstream R&D to downstream market operations**. This will not only **enhance our core technological autonomy and market share**, but also **create sustainable value and contribution for our shareholders and society**.

Research and Development Project



● API

Progress	Product	Indication	*Global market scale (USD)	*Global market scale (kg)
Process Validation Completed	SBT	Heart failure treatment	10,440 M	271,216
	EDV	Amyotrophic lateral sclerosis	703 M	1,229
	MRG	Overactive bladder	3,326 M	59,637
	ZPT	Insomnia	592 M	33,752
	RVB	Anticoagulant	12,834 M	73,541
	PLC	Local anesthetic(injection)	238 M	15,915
Validation	VY05	Kidney Disease	-	Scale up batch sizes
	TOP	Hyponatremia	708 M	1,926
Pilot-scale	DAT	Chronic Kidney Disease(CKD)	80.4 M	200.3
	CPS	Myocardial infarction	2,300 M	1,107,340
R&D Phase	VBG	Overactive Bladder	1,484 M	22,868
	UDT	Rheumatoid Arthritis	9,897 M	2,197
	BEX	Diabetes medication	0.8M	10.5

*Source: Cortellis™ Generics Intelligence Data

Research and Development Project



● Speciality Chemicals & Pharmaceutical Ingredients

Progress	Product	Indication	Area	Quantity (KG/YEAR)
Process Development Completed (Make-to-order period)	TX06	Speciality chemical	TW/JP	300
	TX07	Speciality chemical	TW/JP	2,000
	TX08	Speciality chemical	TW/JP	3,600~4,800
Process Development Completed (Customer during Sample Test)	TX04	Speciality chemical	TW/JP	500~1,000
Process Development Period	HBP	Pharmaceutical ingredient	TW/JP	200
	AIP	Pharmaceutical ingredient	TW/JP	200
	HBO	Pharmaceutical ingredient	TW/JP	50
	CTA	Resolving agent	TW/JP	260
	HPH	Intermediate	TW/JP	65

Thank you for your attention !

Q & A